Replies to post #186909 on Biotech Values

[mcbio]

TKAI

For those interested, US sales of Xtandi for the quarter came in at 230 million. In my opinion, this is a really solid drug with increasing revenues. There is a strong development roadmap for enzalutamide, so the only glaring weakness in MDVN is the lack of a pipeline.

What are your thoughts on TKAI as a potential competitor/player in this space down the road? I think I heard reference in a recent TKAI CC to there being multiple parties reporting ARV7 as a legit resistance mechanism in CRPC. If true, and if TKAI drug truly works on ARV7 (early days for sure), it would seem they might have an angle to compete in this space. I think the initial focus of the drug is to see if it works in enzalutamide failures so not a direct competitor per se (at least initially).